Naegis Pharmaceuticals Inc.: federal grants and contributions: 11 agreements; $1.5M value; 1 departments; 3 programs.
Assay record ASY-CA-168C8821US · Cite as: Assay Systems, “Naegis Pharmaceuticals Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/naegis-pharmaceuticals-inc/
An new anti-inflammatory compound will be advanced into formulation optimization, chemical scale-up and efficacy profiling studies in ocular inflammatory disorders.
This project involves preclinical studies that will be performed to support development of the firm's lead molecule, an inhibitor of leukotriene production, as a potential novel therapy for inflammatory eye diseases.
The project will involve conducting proof of concept in vivo efficacy and isolation of an optically pure lead compound to support development of a novel therapeutic as a potential treatment for certain sight-threatening ocular inflammatory disorders.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.